DATE – Talk Bio

Diamyd Medical’s Pivotal Phase 3 Type 1 Diabetes Trial Clears Final Safety Review Ahead of Early Readout in March 2026

2 weeks ago talkbio0Tagged Accelerated, approval pathway, Data Safety, Diabetes Mellitus, Insulin-Dependent, DIAGNODE-3, Diamyd Medical, DSMB, fast-track designation, Genotype, HLA DR3-DQ2, interim readout, Monitoring Board, orphan drug designation, Phase 3 trial, precision therapy, safety review

Diamyd Medical; Type 1 Diabetes; Phase 3 trial; DIAGNODE-3; safety review; Data Safety Monitoring Board (DSMB); interim readout; March 2026; HLA DR3-DQ2 genotype; Orphan Drug Designation; Fast Track Designation; accelerated approval pathway; precision therapy

Compugen Reports Third Quarter 2025 Results: Earnings Beat, Clinical Progress, and Cash Runway Extended

2 weeks ago talkbio0Tagged AstraZeneca, cash runway, Clinical Trials, clinical-stage immunotherapy, COM503, COM701, Compugen, earnings beat, Gilead, GS-0321, net loss, Revenue, rilvegostomig, third quarter 2025

Compugen; third quarter 2025; earnings beat; clinical-stage immunotherapy; revenue; net loss; cash runway; clinical trials; COM701; COM503 (GS-0321); rilvegostomig; AstraZeneca; Gilead

Spotlight On: What to Watch at AHA 2025 – Key Science and Trends

2 weeks ago talkbio0Tagged 2025, Autoimmune hemolytic anemia, Cardiology discipline, cardiometabolic, Cardiopulmonary Resuscitation, Clinical Trials, coronary trials, gene editing therapies, Guidelines, Hypertensive disease, Interventional procedure, lipid management, Medical Valves, polypill, Science

AHA 2025; late-breaking science; clinical trials; cardiology; gene-editing therapies; polypill; lipid management; valve and coronary trials; cardiometabolic intervention; hypertension; CPR guidelines

Recent News on Upcoming and On-Demand Webinars (November 2025)

2 weeks ago talkbio0Tagged business career, Event, Intrathecal Route of Drug Administration, nonprofit webinars, November 2025, On-Demand Webinars, webinar calendar, webinars

upcoming webinars; on-demand webinars; webinar calendar; November 2025 events; nonprofit webinars; IT webinars; business webinars

Vir Biotechnology’s Phase 2 Data for Hepatitis D Combo Regimen Highlights Market Potential

2 weeks ago talkbio0Tagged Clinical Trials, Combined Modality Therapy, ECLIPSE program, elebsiran, HDV RNA, Hepatitis D Infection, Market, Phase 2, SOLSTICE, tobevibart, Undetectable, Vir Biotechnology

Vir Biotechnology; Phase 2; hepatitis D; combination therapy; tobevibart; elebsiran; SOLSTICE trial; undetectable HDV RNA; market potential; ECLIPSE program

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Highlighting Integration of Clinical Innovation, Multi-Omics, and AI for Solid Tumor Therapies

3 weeks ago talkbio0Tagged Artificial Intelligence, CAN-2409, Candel Therapeutics, enLIGHTEN Discovery Platform, Immunotherapy, Malignant neoplasm of prostate, Multiomics, Non-Small Cell Lung Carcinoma, Precision Medicine, SITC, Solid Neoplasm

Candel Therapeutics; SITC 2025; immunotherapy; CAN-2409; multi-omics; artificial intelligence; solid tumors; enLIGHTEN Discovery Platform; prostate cancer; non-small cell lung cancer; precision medicine

Spotlight On: VC Deal Flow – October’s Haul Sets 2025 up to Run Rings Around Previous Year

3 weeks ago talkbio0Tagged 2025, Deal Flow, Exit activity, funding rounds, Investments, Megadeals, October, Sector, Trail Making Test, Unicorn births, venture capital

Venture Capital; Deal Flow; 2025; October Funding; AI investment; Megadeals; Exit activity; TMT sector; Funding rounds; Unicorn births

Life Biosciences Appoints Industry Veteran David Guyer, M.D. to Board of Directors

3 weeks ago talkbio0Tagged Aging, Biotechnology, board of directors, cellular rejuvenation, David Guyer, Drug Development, epigenetic reprogramming, ER-100, Life Biosciences

Life Biosciences; David Guyer; Board of Directors; biotechnology; cellular rejuvenation; epigenetic reprogramming; ER-100; aging; drug development

Viking Therapeutics to Highlight VK2735 Clinical Data at ObesityWeek 2025

4 weeks ago talkbio0Tagged Clinical Data, Clinical Trials, GLP-1/GIP Dual Agonist, Metabolic Syndrome X, Obesity, ObesityWeek 2025, Prediabetes syndrome, VANQUISH-1, venture, Viking Therapeutics, VK2735

Viking Therapeutics; VK2735; ObesityWeek 2025; VENTURE trial; VANQUISH-1 trial; GLP-1/GIP dual agonist; clinical data; obesity; prediabetes; metabolic syndrome

BioMarin Plans to Divest Hemophilia Gene Therapy Roctavian Amid Strategic Refocus

4 weeks ago talkbio0Tagged BioMarin, Divestment, gene therapy, Hemophilia A, out-licensing, portfolio strategy, Roctavian

BioMarin; Roctavian; hemophilia A; gene therapy; divestment; out-licensing; portfolio strategy; third quarter 2025; revenue challenge